Diagnostic value of 18F-FDG PET/CT in primary and metastatic renal tumors: a pilot study
Clinical and Translational Imaging - Trang 1-7 - 2023
Tóm tắt
We aimed to evaluate 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) derived parameters in primary and metastatic renal tumors. A total of 47 patients with renal malignant tumors who underwent assessment in our department between December 2015 and March 2022 were enrolled in this study. The diagnoses were confirmed by biopsy or surgical resection plus histological study. Clinical and imaging information were collected. Comparisons among groups were performed with the independent sample t test or Mann–Whitney U test, as appropriate. Logistic regression and ROC curve analysis were used to calculate and compare the diagnostic value of 18F-FDG PET/CT in primary renal malignant tumors and metastatic renal malignant tumors. The maximum diameter and metabolic tumor volume (MTV) of primary renal tumors were larger than those of metastatic renal tumors, which had a smaller maximum diameter and MTV. Primary renal tumors are smaller than metastatic renal tumors in terms of maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), peak standardized uptake value (SUVpeak), tumor-to-background ratio (TBR), and tumor-to-liver ratio (TLR). The SUVmax of clear cell primary renal carcinoma was lower than the SUVmax of clear cell primary renal carcinoma. Metastatic renal tumors associated with squamous lung cancer had a higher SUVmax than those associated with non-squamous lung cancer. 18F-FDG PET/CT may be a useful imaging modality for detecting primary renal tumors and metastatic renal tumors and may provide valuable information for the differential diagnosis of primary renal tumors and metastatic renal tumors. The SUV, TBR, TLR, maximum diameter, and MTV of a renal mass are potential predictive factors to distinguish primary and metastatic renal tumors. In addition, 18F-FDG PET/CT revealed differences in metabolic activity based on the histopathological type of renal tumors, which may help to individualize treatment.
Tài liệu tham khảo
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7
Zhou C, Urbauer DL, Fellman BM et al (2016) Metastases to the kidney:a comprehensive analysis of 151 patients from a tertiary referral center. BJU Int 117(5):775–782
Hollingsworth JM, Miller DC, Daignault S et al (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98:1331–1334
Aron M, Nair M, Hemal AK (2004) Renal metastasis from primary hepatocellular carcinoma. A case report and review of the literature. Urol Int 73:89–91
Martino L, Martino F, Coluccio A et al (2004) Renal metastasis from pancreatic adenocarcinoma. Arch Ital Urol Androl 76:37–39
Muller HJ, Weckesser M, Schober O (2000) Bilateral renal metastasis in follicular thyroid carcinoma. Nuklearmedizin 39:45–47
Ho L, Wassef H, Henderson R, Seto J (2009) Renal metastasis from primary colon cancer on FDG PET-CT. Clin Nucl Med 34:596–597
Ng CS, Wood CG, Silverman PM et al (2008) Renal cell carcinoma: diagnosis, staging, and surveillance. Am J Roentgenol 191:1220–1232
Krajewski KM, Pedrosa I (2018) Imaging advances in the management of kidney cancer. J Clin Oncol 29:36
Xuan D, Wen W, Tian S et al (2020) Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 99
Fletcher JW, Djulbegovic B, Soares H et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508
Aras M, Dede F, Ones T et al (2013) Is the value of FDG PET/CT in evaluating renal metastasis underestimated? a case report and review of the literature. Mol Imaging Radionucl Ther 22(3):109–112
Ji X, Dong A (2022) FDG PET/CT in unilateral renal metastasis from colon cancer. Clin Nucl Med 47(11):1000–1002
Kaneta T, Hakamatsuka T, Yamada T et al (2006) FDG PET in solitary metastastic/secondary tumor of the kidney: a report of three cases and a review of the relevant literature. Ann Nucl Med 20(1):79–82
Zhou C, Urbauer DL, Fellman BM et al (2016) Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int 117(5):775–782
Kumar R, Chauhan A, Lakhani P et al (2005) 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol 7:431–439
Kang D, White RL Jr, Zuger J et al (2004) Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. Urol 171:1806–1809
Ozulker T, Ozulker F, Ozbek E et al (2011) A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun 32:265–272
Khandani AH, Cowey LC, Moore DT et al (2012) Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun
Takehara K, Koga S, Nishikido M et al (1999) Breast cancer metastatic to the kidney. Anticancer Res 19:5571–5573
Sakata R, Iwasaki A et al (2011) Renal metastasis from prostatic adenocarcinoma: a case report. Hinyokika Kiyo 57(12):683–687
Trompette A, Clavel M, Paraf F et al (1999) Symptomatic renal metastases of bronchial carcinoma. Rev Mal Respir 16:833–835
Aide N, Cappele O, Bottet P et al (2003) Efficiency of [18F]FDG PET in characterizing renal cancer and detecting distant metastases:a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236–1245
Nakajima R, Matsuo Y, Kondo T et al (2017) Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with renal cell carcinoma. Clin Nuclear Med 42
de Llano SRM, Delgado-Bolton RC, Jimenez-Vicioso A et al (2007) Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma. Rev Esp Med Nucl 26:19–29
Ma H, Shen G, Liu B et al (2017) Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun 38(2):156–163
Yin Q, Xu H, Zhong Y et al (2022) Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer 22(1):163
Saeed F, Osunkoya AO (2022) Secondary tumors of the kidney: a comprehensive clinicopathologic analysis. Adv Anat Pathol 29(4):241–251
Li Y, Zheng R, Zhang Y et al (2023) Special issue “The advance of solid tumor research in China”: 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer 152(1):42–50
Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31:187–194
van Oostenbrugge TJ, Langenhuijsen JF, Oosterwijk E et al (2020) Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with (111) In-girentuximab. Eur J Nucl Med Mol Imaging 47:1864–1870
Verhoeff SR, van Es SC, Boon E et al (2019) Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 46:1931–1939